ZA932351B - Imidazole derivatives their method of preparation and their application in therapeutics - Google Patents

Imidazole derivatives their method of preparation and their application in therapeutics

Info

Publication number
ZA932351B
ZA932351B ZA932351A ZA932351A ZA932351B ZA 932351 B ZA932351 B ZA 932351B ZA 932351 A ZA932351 A ZA 932351A ZA 932351 A ZA932351 A ZA 932351A ZA 932351 B ZA932351 B ZA 932351B
Authority
ZA
South Africa
Prior art keywords
therapeutics
preparation
application
imidazole derivatives
imidazole
Prior art date
Application number
ZA932351A
Inventor
Pierre Dodey
Michel Bondoux
Patrice Renaut
Patrice Pruneau
Original Assignee
Fournier Ind & Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Ind & Sante filed Critical Fournier Ind & Sante
Publication of ZA932351B publication Critical patent/ZA932351B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/62—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with triarylmethyl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA932351A 1992-04-01 1993-04-01 Imidazole derivatives their method of preparation and their application in therapeutics ZA932351B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR929203944A FR2689508B1 (en) 1992-04-01 1992-04-01 IMIDAZOLE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION.

Publications (1)

Publication Number Publication Date
ZA932351B true ZA932351B (en) 1994-10-03

Family

ID=9428340

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA932351A ZA932351B (en) 1992-04-01 1993-04-01 Imidazole derivatives their method of preparation and their application in therapeutics

Country Status (13)

Country Link
EP (1) EP0564356A1 (en)
JP (1) JPH06263743A (en)
KR (1) KR930021622A (en)
CN (1) CN1081438A (en)
AU (1) AU3554693A (en)
CA (1) CA2092852A1 (en)
FI (1) FI931414A (en)
FR (1) FR2689508B1 (en)
HU (1) HUT64752A (en)
MX (1) MX9301882A (en)
NO (1) NO931186L (en)
TW (1) TW232012B (en)
ZA (1) ZA932351B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015817A (en) * 1996-12-05 2000-01-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
UA71587C2 (en) * 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Anthranilic acid amides and use thereof as medicaments
DE10023486C1 (en) * 2000-05-09 2002-03-14 Schering Ag Ortho substituted anthranilic acid amides and their use as medicines
WO2003006012A1 (en) * 2001-07-11 2003-01-23 Yale University Compounds and methods for the inhibition of trypanosoma cruz i
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
UA89035C2 (en) 2003-12-03 2009-12-25 Лео Фарма А/С Hydroxamic acid esters and pharmaceutical use thereof
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1752450A1 (en) 2005-08-01 2007-02-14 Merck Sante Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them
BRPI0811264A2 (en) 2007-05-24 2014-11-04 Eldrug S A COMPOUNDS
GR1006917B (en) * 2007-10-24 2010-07-30 Ελληνικα Φαρμακα Ερευνα Και Αναπτυξη Eldrug Α.Ε., Angiotensin ii receptor antagonists based on histamin with sympathetic suppressant properties ans synthetic methods in the treatment of hypertension and cardiovascular diseases
EP2188279A2 (en) * 2007-08-01 2010-05-26 Eldrug S.A. 1,3 and 1,3,5 substituted imidazoles as antihypertensiva
NZ591820A (en) 2008-08-27 2012-12-21 Leo Pharma As Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors
CN102584709B (en) * 2011-12-19 2016-08-17 浙江华海药业股份有限公司 A kind of preparation technology of the Eprosartan intermediate aryl imidazole aldehyde of improvement
JP7197880B2 (en) * 2017-10-19 2022-12-28 学校法人 名城大学 Esterifying agent and its use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2110663B (en) * 1981-12-04 1985-08-07 Farmos Group Ltd Imidazole derivatives
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
ATE250587T1 (en) * 1989-06-14 2003-10-15 Smithkline Beecham Corp IMIDAZOALGENIC ACID
CA2018443A1 (en) * 1989-06-14 1990-12-14 Joseph A. Finkelstein Imidazolyl-alkenoic acids
AU640417B2 (en) * 1989-10-25 1993-08-26 Smithkline Beecham Corporation Substituted 5-((tetrazolyl)alkenyl)imidazoles
CA2028925A1 (en) * 1989-11-06 1991-05-07 Gerald R. Girard Substituted n-(imidazolyl)alkyl alanine derivatives
GB8927928D0 (en) * 1989-12-11 1990-02-14 Roussel Lab Ltd Chemical compounds
NZ239161A (en) * 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,

Also Published As

Publication number Publication date
HUT64752A (en) 1994-02-28
CN1081438A (en) 1994-02-02
TW232012B (en) 1994-10-11
EP0564356A1 (en) 1993-10-06
CA2092852A1 (en) 1993-10-02
NO931186L (en) 1993-10-04
KR930021622A (en) 1993-11-22
FR2689508A1 (en) 1993-10-08
NO931186D0 (en) 1993-03-30
FI931414A (en) 1993-10-02
JPH06263743A (en) 1994-09-20
AU3554693A (en) 1993-10-07
HU9300942D0 (en) 1993-06-28
FR2689508B1 (en) 1994-06-17
FI931414A0 (en) 1993-03-29
MX9301882A (en) 1994-06-30

Similar Documents

Publication Publication Date Title
ZA937155B (en) Piperidine derivatives their preparation and theirapplication in therapeutics
EP0578426A3 (en) Improvements in and relating to powder coating
ZA932351B (en) Imidazole derivatives their method of preparation and their application in therapeutics
EP0578469A3 (en) Improvements in and relating to applying coatings
IL111148A0 (en) Imidazol-4- ylpiperidine derivatives, their preparation and their application in therapeutics
ZA9410056B (en) Indoline derivatives method of preparation and use
IL103772A0 (en) Bloodbag and method of making same
AU2952192A (en) Highlighting preparation and method of use
PL296034A2 (en) Composition exibiting-fgf activity and method of obtaining same
ZA953140B (en) Naphthalene derivatives method of preparation and use
EP0513796A3 (en) Composite structure and method of making
AP9300575A0 (en) Piperidine derivatives their preparation and their application in therapy
HUP9801158A3 (en) Imidazole derivatives and medicinal composition thereof
ZA9410004B (en) Aminosulphonyl-phenyl-1h-pyrrole derivatives method of their preparation and their use
ZA933899B (en) Thienothiazine derivatives process for their preparation and their use
AU1307592A (en) Improvements in or relating to methods of and/or apparatus for forming joints
ZA941532B (en) Novel 2-}henoxyethylamine derivatives their preparation and their application in therapeutics
PL302373A1 (en) Derivatives of substituted imidazobenzoxazin-1-one and method of obtaining them
ZA967558B (en) Alpha-phenylpiperidine-1-propanol derivatives their preparation and their application in therapeutics
CS818488A1 (en) Imidazole derivatives and method of their preparation
ZA939333B (en) 3-(6-quinolylmethyl)-4H-imidazol-4-one derivatives their preparation and their application in therapy
PL299871A1 (en) Method of obtainingenamines in aqueous environment
GB9201224D0 (en) Difluoromethylenandrostenone derivatives and process for their preparation
HU9401502D0 (en) Intermediates useful in the preparation of pyranyl-cyanoguanidine derivatives and methods of preparing same
SK62693A3 (en) 3-/2-alkylthio-6-benzothiazolylaminomethyl/-2- benzoxazolinthiones and method of their preparation